Clinical trial
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin…
NCT00117689 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00117689 |
|---|---|
| Title | Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection |
| Official title | A Randomized, Controlled, Multi-Center Study of Thymoglobulin Induction Therapy With a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Dysfunction, Rejection, Transplant, Transplantation, Liver |
| Intervention type | Biological, Drug |
| Interventions | Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil |
| Enrollment | 75 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jul 8, 2005 |
| Last update posted | Mar 18, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: